LABELS · af340f13-7954-4974-845d-ae55e0b56512

Fragmin

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-09-30
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7) ] . WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis ( 5.1 , 7 ).

Indications and usage: exact source text

1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] . 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) . 1.5 Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE.

Full extracted label fields

application numbers

NDA020287

boxed warning exact

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7) ] . WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis ( 5.1 , 7 ).

brand names

Fragmin

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7

generic names

DALTEPARIN SODIUM

af340f13-7954-4974-845d-ae55e0b56512

indications and usage exact

1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] . 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) . 1.5 Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE.

indications and usage tables exact

is original packager

true

manufacturer names

Pfizer Laboratories Div Pfizer Inc

matched search terms

cancer

package ndcs

0069-0195-01
0069-0195-02
0069-0196-01
0069-0196-02
0069-0206-01
0069-0206-02
0069-0217-01
0069-0217-02
0069-0220-01
0069-0220-02
0069-0223-01
0069-0223-02

product ndcs

0069-0195
0069-0196
0069-0206
0069-0217
0069-0220
0069-0223
0069-0228
0069-0232
0069-0253

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage, Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients ( 1.4 ) 10/2024 Dosage and Administration, Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients ( 2.4 ) 10/2024 Dosage and Administration, Dose Reductions for Thrombocytopenia in Adult Patients with Cancer and in Pediatric Patients with Symptomatic VTE ( 2.5 ) 10/2024

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

978725
978727
978733
978735
978736
978737
978740
978741
978744
978745
978746
978747

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA020287

brand names

Fragmin

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 286
end exclusive: true
exact text: 1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or me
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 0

current approval status

not_reconciled

duplicate text group

dup-7dee443d9762bb597f33

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-40515bc41003df004927

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

end: 82
end exclusive: true
exact text: is a low molecular weight heparin (LMWH) indicated
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 86
end exclusive: true
exact text: 1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 390
end exclusive: true
exact text: 1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of sy
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 0

current approval status

not_reconciled

duplicate text group

dup-ebb59ad34c2c2bbd9c3d

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-c89691146f540e4c6ea2

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 190
end exclusive: true
exact text: • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 )
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 87

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 563
end exclusive: true
exact text: 1 INDICATIONS AND USAGE FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment a
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 0

current approval status

not_reconciled

duplicate text group

dup-85875e4996de0692688d

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-936edbad11e0539eeee4

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 363
end exclusive: true
exact text: • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 )
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 191

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 684
end exclusive: true
exact text: cardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in p
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 164

current approval status

not_reconciled

duplicate text group

dup-aa72ac8208a28c887c58

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-b193563b9f4520faf7d7

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

context exact
ic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer.
kind
age
polarity
not_inferred
span
end
471
end exclusive
true
exact text
adult patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
457

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 484
end exclusive: true
exact text: • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer.
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 364

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 798
end exclusive: true
exact text: edical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indic
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 285

current approval status

not_reconciled

duplicate text group

dup-2f50157773b249be0e8e

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-267cbd94b0cd0178c06b

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 598
end exclusive: true
exact text: In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 )
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 485

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 956
end exclusive: true
exact text: venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injectio
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 399

current approval status

not_reconciled

duplicate text group

dup-dda77ea06418ff236de6

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-d7450475daa2a1a7a73d

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

context exact
ic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 )
kind
age
polarity
not_inferred
span
end
701
end exclusive
true
exact text
pediatric patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
683

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 756
end exclusive: true
exact text: • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 )
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 599

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · limitation of use

application numbers

NDA020287

brand names

Fragmin

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1041
end exclusive: true
exact text: ment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and n
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 557

current approval status

not_reconciled

duplicate text group

dup-b85f114ad73378762850

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-ccedf20387bd9ea2eeb6

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 841
end exclusive: true
exact text: • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 )
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 757

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · positive indication candidate

application numbers

NDA020287

brand names

Fragmin

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1358
end exclusive: true
exact text: bolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement sur
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 642

current approval status

not_reconciled

duplicate text group

dup-1bfb6992cdc0dc30d7d3

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-46fd4a4307492735c8fc

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

end: 970
end exclusive: true
exact text: is indicated
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 958

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1158
end exclusive: true
exact text: 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] .
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 842

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

NDA020287

brand names

Fragmin

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1513
end exclusive: true
exact text: s indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 959

current approval status

not_reconciled

duplicate text group

dup-33d1acdcf35a2603a040

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-21b1c138d7e19ea7b1e9

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

end: 1219
end exclusive: true
exact text: is indicated
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1207

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1313
end exclusive: true
exact text: 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1159

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1595
end exclusive: true
exact text: rin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1114

current approval status

not_reconciled

duplicate text group

dup-d745ac2255cdad628a1d

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-9d049667793e9745ecad

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1395
end exclusive: true
exact text: • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ;
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1314

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1720
end exclusive: true
exact text: is FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1196

current approval status

not_reconciled

duplicate text group

dup-fa9a4072d4c1e639893c

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-1dd01c77ff5d4b535e5d

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1520
end exclusive: true
exact text: • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ;
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1396

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1881
end exclusive: true
exact text: tients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1321

current approval status

not_reconciled

duplicate text group

dup-877f487b38b6fb1bc0a4

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-f324810b9dc25f62dab8

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1681
end exclusive: true
exact text: • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] .
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1521

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

NDA020287

brand names

Fragmin

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2159
end exclusive: true
exact text: tions [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] . 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1482

current approval status

not_reconciled

duplicate text group

dup-9e4cb074784414377db8

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-f13bfabac75b52f86c4e

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

end: 1799
end exclusive: true
exact text: is indicated
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1787

qualifier mentions

context exact
ed Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment
kind
age
polarity
not_inferred
span
end
1766
end exclusive
true
exact text
Adult Patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
1752
context exact
proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer.
kind
age
polarity
not_inferred
span
end
1946
end exclusive
true
exact text
adult patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
1932

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1959
end exclusive: true
exact text: 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer.
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1682

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 14 · unclassified context

application numbers

NDA020287

brand names

Fragmin

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2298
end exclusive: true
exact text: tients with Cancer FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] . 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in p
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1760

current approval status

not_reconciled

duplicate text group

dup-424dafe881ed01ef01a0

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-c73c860bb9da79fe6f9d

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2098
end exclusive: true
exact text: In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] .
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1960

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · positive indication candidate

application numbers

NDA020287

brand names

Fragmin

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2444
end exclusive: true
exact text: reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months [see Clinical Studies (14.5) ] . 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) . 1.5 Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE.
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 1899

current approval status

not_reconciled

duplicate text group

dup-c3f839e1822e8d5bcf31

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-6f82a6ae50149d08b919

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

end: 2199
end exclusive: true
exact text: is indicated
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 2187

qualifier mentions

context exact
.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venou
kind
age
polarity
not_inferred
span
end
2178
end exclusive
true
exact text
Pediatric Patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
2160
context exact
us thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) .
kind
age
polarity
not_inferred
span
end
2315
end exclusive
true
exact text
pediatric patients
label id
af340f13-7954-4974-845d-ae55e0b56512
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start
2297

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2364
end exclusive: true
exact text: 1.4 Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) .
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 2099

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 16 · limitation of use

application numbers

NDA020287

brand names

Fragmin

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2444
end exclusive: true
exact text: tric Patients FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks) . 1.5 Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE.
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 2165

current approval status

not_reconciled

duplicate text group

dup-09cfd32e8febc4d6a5dc

extraction review status

automated_candidate_pending_source_review

generic names

DALTEPARIN SODIUM

ind-span-302f24e5ba6756fa199c

label id

af340f13-7954-4974-845d-ae55e0b56512

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2444
end exclusive: true
exact text: 1.5 Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE.
label id: af340f13-7954-4974-845d-ae55e0b56512
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3c1114cceab0ba98c7c9a8d1680becd8dd77a538d27f09611fc51343fa64034f
start: 2365

source url

https://api.fda.gov/drug/label.json?search=id%3A%22af340f13-7954-4974-845d-ae55e0b56512%22

spl effective date

2025-09-30

spl set id

23527b8b-9b28-4e6d-9751-33b143975ac7

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice